Over a 24-week period, responders exhibited significant improvements in disease activity score (DAS)28, swollen joint counts, body weight, and HbA1C, whereas non-responders showed no notable changes
Regular follow-up with a healthcare provider is recommended to monitor treatment response and tolerability
10.1016/J.NEUROBIOLAGING.2015.10.016 14 AndersenP
What a strong LMN includes: your diagnosis codes and clinical history, baseline BMI and weight trajectory, documented comorbidities (with cardiovascular disease, MASH, sleep apnea, and prediabetes being especially relevant for Wegovy appeals), a summary of prior treatments and why they were insufficient, supporting clinical evidence like the STEP trials for weight management, the SELECT trial for cardiovascular outcomes, and the ESSENCE trial for MASH, and a clear explanation of why Wegovy specifically, rather than just "a GLP-1," is the right choice
N Engl J Med 2023;388:117-27.ArticlePubMed 50
About Mesocartin (L-Carnitine 2g)